|
|
Clinical effect of GnRHa combined with LNG-IUS regimen in the treatment of adenomyosis |
YU Lingyun1 HUANG Xiaoqin2 SHEN Hengchun1▲ |
1.Department of Obstetrics and Gynecology, Affiliated Hospital of Southwest Medical University, Sichuan Province, Luzhou 646000, China;
2.Department of Obstetrics and Gynecology, Neijiang First People’s Hospital, Sichuan Province, Neijiang 641000, China |
|
|
Abstract Objective To investigate the clinical effect of gonadotropin-releasing hormone agonist (GnRHa) combined with levonorgestrel intrauterine release system (LNG-IUS) in the treatment of adenomyosis. Methods A total of 90 patients with adenomyosis admitted to Neijiang First People’s Hospital of Sichuan Province from May 2018 to January 2021 were selected. They were divided into two groups by random number table method, with 45 cases in each group. The experimental group was given GnRHa and LNG-IUS combined treatment, and the control group was given single GnRHa treatment. Visual analogue scale (VAS), menstrual volume score, uterine volume, endometrial thickness, and carbohydrate antigen-125 (CA125) level were compared between two groups before treatment, six months after treatment, and one year after treatment, and the occurrence of adverse reactions was observed. Results Six months and one year after treatment, VAS score, uterine volume, endometrial thickness, menstrual volume score, and CA125 between two groups were less than those before treatment, and the differences were statistically significant (P<0.05). One year after treatment, VAS score of the experimental group was lower than that six months after treatment; VAS score, endometrial thickness, and CA125 of control group were lower than those six months after treatment, and the differences were statistically significant (P<0.05). Six months after treatment, VAS score, uterine volume, endometrial thickness, menstrual volume score, and CA125 of experimental group were lower than those of control group, and the differences were statistically significant (P<0.05). One year after treatment, VAS score, uterine volume, menstrual volume score, and CA125 of experimental group were lower than those of control group, and the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between two groups (P>0.05). Conclusion The combination of GnRHa and LNG-IUS in the treatment of adenomyosis has a better curative effect and a superior application prospect.
|
|
|
|
|
[1] 张楠,苏敏君,周剑国,等.高强度聚焦超声联合GnRHa治疗子宫腺肌病的长期疗效分析[J].中国计划生育和妇产科,2021,13(6):76-80.
[2] 陈君霞,王运根,章英,等.促性腺激素释放激素激动剂对子宫腺肌病病灶及子宫内膜Ki-67、VEGF、NGF表达及神经纤维分布的影响[J].浙江医学,2021,43(21):2289- 2293.
[3] 徐锋,镡丽霞,李盼,等.高强度聚焦超声消融联合GnRHa治疗子宫腺肌病的临床研究[J].国际妇产科学杂志,2019,46(6):618-620,640.
[4] 王文莉,张颖,郭银树,等.GnRH-a联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床疗效研究[J].医学综述,2018,24(13):2689-2692.
[5] 吴青,林坦,刘越.腹腔镜子宫腺肌瘤切除联合子宫动脉阻断术对内膜白血病抑制因子的影响[J].中华生殖与避孕杂志,2018,38(4):315-318.
[6] 彭燕蓁,段华,郭银树,等.腹腔镜子宫腺肌病灶切除术术后复发危险因素分析[J].国际妇产科学杂志,2019,46(2):237-240.
[7] 杨洋.LNG-IUS联合GnRH-a治疗子宫腺肌病的临床疗效观察[J].中国妇幼保健,2019,34(23):5385-5387.
[8] 谢幸,孔北华.妇产科学[M].8版.北京:人民卫生出版社,2018:268-270.
[9] 宗行万之助.疼痛的估价——用特殊的视觉模拟评分法作参考(VAS)[J].实用疼痛学杂志,1994(4):1.
[10] 王慧丽,范晓芳,张琳.肌壁大部切除-子宫重建术联合左炔诺孕酮宫内缓释系统治疗中重度子宫腺肌病的疗效及对卵巢功能的影响[J].安徽医药,2018,22(12):2375-2378.
[11] 李梦如,陈欢,张红,等.GnRHa与子宫腺肌症相关研究进展[J].中国性科学,2018,27(7):79-82.
[12] 周琴,徐晓燕,蒋婧婧,等.经阴道三维彩色多普勒超声在子宫腺肌病诊断及治疗中的应用价值[J].现代妇产科进展,2018,27(3):215-217.
[13] 李爱萍.促性腺激素释放激素激动剂及左炔诺孕酮宫内缓释系统辅助治疗子宫腺肌病的效果及对痛经程度及生存质量的影响[J].中国妇幼保健,2018,33(7):1478- 1480.
[14] 蒋静,周洪贵,陈燕,等.高强度聚焦超声联合促性腺激素释放激素激动剂治疗子宫腺肌症的前瞻性研究[J].重庆医学,2019,48(10):1705-1708.
[15] 邢雅纯,凌秀凤,苏雁,等.冻融胚胎移植中降调节激素替代周期的研究进展[J].国际生殖健康/计划生育杂志,2020,39(3):233-237.
[16] 刘琰,陈雁南,白杨,等.子宫腺肌病患者放置LNG-IUS发生异位的因素分析[J].医学研究杂志,2020,49(1):81-83,136.
[17] 丁淼,王良岸,李扬志,等.坤泰胶囊改善GnRH-a所致围绝经期症状的前瞻性随机对照研究[J].中国实用妇科与产科杂志,2019,35(4):462-465.
[18] 吴子玉,潘姿璇,吕秀萍,等.高强度聚焦超声联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病临床观察[J].山东医药,2018,58(3):65-67.
[19] 袁静,段华,孟戈,等.GnRH-a联合LNG-IUS在不同子宫体积时对子宫腺肌病疗效的影响分析[J].中国实用妇科与产科杂志,2019,35(8):910-914.
[20] 许荣海,黄美虹,许幼仕.醋酸亮丙瑞林联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病的效果[J].中国妇幼保健,2021,36(13):2932-2934.
[21] 范文生,王铭洋,杨雯,等.磁共振引导聚焦超声联合GnRHa治疗子宫腺肌症1例[J].中国医学影像学杂志,2019,27(9):719-720.
[22] 卢利霞,边文会.中西医治疗子宫腺肌病研究进展[J].河北中医药学报,2019,34(3):54-58.
[23] 杜洁贤,王康,田彩,等.不同预处理方式对曼月乐治疗弥漫性大子宫腺肌病效果的影响研究[J].中国妇幼保健,2020,35(2):199-202.
[24] 郎景和,陈春林,向阳,等.子宫肌瘤及子宫腺肌病子宫动脉栓塞术治疗专家共识[J].中华妇产科杂志,2018, 53(5):289-293.
[25] 邓少君,林元媚,张瑶瑶.GnRH-α治疗子宫腺肌病患者的效果探讨[J].中国医药科学,2020,10(3):93-95, 105.
[26] 杨颖琼,黄勤瑾.曼月乐治疗妇科常见疾病的研究进展[J].中华生殖与避孕杂志,2020,40(3):255-258.
[27] 石玉萍,张银芳,周玉红.LNG-IUS联合GnRH-a治疗子宫腺肌病的临床效果分析[J].中外医学研究,2022, 20(19):129-132. |
|
|
|